Test Price
2,800 AED✅ Home Collection Available
GPD1L Gene Brugada Syndrome Type 2 Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 accredited Next‑Generation Sequencing (NGS) processing in our UAE-based laboratory with Sanger confirmation of all reported variants.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM by DHA‑licensed practitioners, utilizing ISO‑certified transport maintaining sample stability from 22°C to -20°C.
- Clinical Guidance: Complimentary post‑test telephonic genetic counselling session to interpret your GPD1L variant result and its implications for Brugada syndrome type 2 risk stratification.
- Insurance & Billing: Direct insurance verification and pre‑approval assistance via +971 54 548 8731 (WhatsApp).
Test Overview & Methodology
This test sequences the entire coding region and intron‑exon boundaries of the GPD1L gene using Next‑Generation Sequencing (NGS) to detect pathogenic and likely pathogenic variants responsible for Brugada Syndrome Type 2 (BrS2), an inheritable cardiac channelopathy associated with life‑threatening ventricular arrhythmias and sudden cardiac death. Bioinformatic alignment uses the GRCh38 human genome build with a read depth exceeding 100×, and all clinically significant variants are confirmed via Sanger sequencing prior to reporting.
| Test Parameter | Our Test (GPD1L NGS) | Closest Alternative |
|---|---|---|
| Precision | Full gene sequencing (all exons, intron‑exon boundaries, 5′ and 3′ UTR) with Sanger confirmation of all pathogenic and VUS variants | Targeted mutation panel limited to common SNP hotspots or single‑exon analysis |
| Methodology | Illumina NovaSeq NGS (read depth >100×) with GRCh38 alignment and ACMG/AMP variant classification | Sanger sequencing of selected exons or array‑based genotyping without full coverage |
| Speed / TAT | 3–4 weeks (expedited analysis in 10 working days available upon request) | 6–8 weeks via international referral laboratory with additional shipping delays |
Physician Insight & Safety Protocols
“A molecular finding in GPD1L must be interpreted within the full clinical context of the patient. A pathogenic variant strongly supports the diagnosis of Brugada syndrome type 2, yet the absence of a variant does not exclude the condition. Correlation with electrocardiographic patterns, pharmacological challenge testing, and family segregation studies remains essential for accurate risk assessment and clinical management.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory: Medication and Clinical Precautions
Do not discontinue, adjust, or initiate any antiarrhythmic medication or cardiovascular therapy without explicit instruction from your treating cardiologist. Beta‑blockers, sodium channel blockers, and other agents may influence ECG manifestations and should be reviewed prior to genetic testing. Always carry your current medication list to any clinical appointment.
Exclusion Criteria & Emergency Red Flags
- Home collection cannot proceed if the patient is febrile (>38°C), has an active bleeding disorder, or is unable to provide informed consent.
- This test is not indicated for individuals under 18 years in the UAE without parental consent and a mandatory pre‑test genetic counselling session in accordance with DHA regulatory standards for pediatric genetic testing.
- Seek immediate emergency care if you experience sudden syncope, unexplained palpitations accompanied by chest pain, seizure‑like activity, or resuscitated sudden cardiac arrest—these may be signs of a malignant arrhythmia requiring urgent evaluation.
Patient FAQ & Clinical Guidance
1. What is the GPD1L gene and how does it relate to Brugada syndrome type 2?
The GPD1L gene encodes glycerol‑3‑phosphate dehydrogenase 1‑like protein, which influences the cardiac sodium channel (Nav1.5) via a mitochondrial redox‑sensitive pathway. Pathogenic variants in GPD1L reduce sodium current density and produce a type 2 Brugada ECG pattern. This test identifies such variants through comprehensive NGS analysis of the entire gene.
2. What sample type is required and how is collection arranged?
We accept whole blood in an EDTA tube (3–5 mL), extracted genomic DNA (minimum 1 µg), or a single blood spot on an FTA card. A DHA‑licensed phlebotomist will visit your home or office between 8 AM and 11 PM for temperature‑controlled specimen collection. Results are typically reported within 3–4 weeks from sample receipt.
3. Why does the report take 3–4 weeks to deliver?
The turnaround time reflects the rigorous multistep workflow: genomic DNA extraction, NGS library preparation, high‑depth sequencing on the Illumina NovaSeq platform, bioinformatic alignment to GRCh38, variant calling with quality filters, manual review of all coding regions, Sanger confirmation of clinically significant variants, and final classification according to ACMG/AMP guidelines. Each step includes independent quality‑control checks to ensure 99.9% analytic sensitivity.
4. Can a negative result rule out Brugada syndrome entirely?
No. A negative GPD1L result reduces the probability of type 2 Brugada syndrome but does not exclude the condition. Approximately 20–25% of individuals with a clinical Brugada phenotype carry variants in other genes (SCN5A, CACNA1C, HCN4, etc.) or may have an unidentified genetic cause. Clinical evaluation including ECG, Holter monitoring, and family history remains essential regardless of the genetic result.
UAE Regulatory & Data Privacy Adherence
- Data Protection: All genetic data is processed and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genomic information is encrypted, access‑restricted, and never shared with third parties without explicit written consent.
- Clinical Safety: Specimen collection, handling, and reporting follow the standards established under Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring traceability and accountability at every stage of the diagnostic pathway.
- DHA Oversight: DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to all Dubai Health Authority guidelines for genetic testing laboratories, including mandatory quality audits and proficiency testing participation.
Clinical & Logistical Metadata
| Test Name | GPD1L Gene Brugada Syndrome Type 2 Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks (expedited: 10 working days) |
| Sample Type / Matrix | Whole blood (EDTA), extracted genomic DNA, or FTA card blood spot |
| Methodology Used | Next‑Generation Sequencing (Illumina NovaSeq, >100× coverage) with Sanger confirmation |
| ICD-10-CM Code | I45.81 |
| LOINC Code | 82176-6 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians